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Abstract. Background: Around 30% of all stage II colon cancer patients will relapse and die of their disease. At present no
objective parameters to identify high-risk stage II colon cancer patients, who will benefit from adjuvant chemotherapy, have
been established. With traditional histopathological features definition of high-risk stage II colon cancer patients is inaccurate.
Therefore more objective and robust markers for prediction of relapse are needed. DNA copy number aberrations have proven to
be robust prognostic markers, but have not yet been investigated for this specific group of patients. The aim of the present study
was to identify chromosomal aberrations that can predict relapse of tumor in patients with stage II colon cancer.
Materials and methods: DNA was isolated from 40 formaldehyde fixed paraffin embedded stage II colon cancer samples
with extensive clinicopathological data. Samples were hybridized using Comparative Genomic Hybridization (CGH) arrays to
determine DNA copy number changes and microsatellite stability was determined by PCR. To analyze differences between stage
II colon cancer patients with and without relapse of tumor a Wilcoxon rank-sum test was implemented with multiple testing
correction.
Results: Stage II colon cancers of patients who had relapse of disease showed significantly more losses on chromosomes
4, 5, 15q, 17q and 18q. In the microsatellite stable (MSS) subgroup (n = 28), only loss of chromosome 4q22.1–4q35.2 was
significantly associated with disease relapse (p < 0.05, FDR < 0.15). No differences in clinicopathological characteristics
between patients with and without relapse were observed.
Conclusion: In the present series of MSS stage II colon cancer patients losses on 4q22.1–4q35.2 were associated with worse
outcome and these genomic alterations may aid in selecting patients for adjuvant therapy.
Keywords: DNA copy number changes, stage II, colon cancer, prognosis
Abbreviations
CGH Comparative Genomic Hybridization;
FFPE Formalin fixed paraffin embedded;
MSS Micro satellite stable;
MSI Inmicro satellite instable;
CRC Colorectal cancer.
1. Introduction
Worldwide, colorectal cancer (CRC) is the third
most common cancer affecting more than 940,000 pa-
*Corresponding author: Gerrit A. Meijer, MD, PhD, Department
of Pathology, VU University Medical Center, P.O. Box 7057, 1007
MB Amsterdam, The Netherlands. Tel.: +31 20 4444772; Fax: +31
20 4442964; E-mail: ga.meijer@vumc.nl.
tients annually. Nearly 500,000 patients die from the
consequences of CRC each year (www.who.int) [43].
In The Netherlands in 2006, 11,231 patients were di-
agnosed with CRC and 4709 CRC related deaths oc-
curred [40]. The incidence of CRC is relatively high
in the western world and steadily increases each year
[40]. Two thirds of all CRCs occur in the colon and one
third is located in the rectum. Patients with colon tu-
mors are treated differently and have a different prog-
nosis compared to rectal cancer patients.
Staging is traditionally based on pathologist’s evalu-
ation of tumor extent, lymph nodes and distant metas-
tasis, all included in the TNM classification [34] and
therapeutic decisions are based on this system. Upon
resection of the primary tumor, some 40% of all colon
cancers appear to be stage II (TNM/UICC) [34]. Of
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patients with stage II colon cancer 20–30% will re-
lapse, i.e. develop distant metastasis, and these patients
will die of their disease. Five-year survival rates for
stage II colon vary between 50% and 90%. Patients
with stage III colon cancer will face relapse of tu-
mor during follow-up in 60% of cases and chemother-
apy can reduce recurrence rates with 31–41% [45].
Although postoperative chemotherapy is standard for
stage III colon cancer it is not for stage II colon cancer
[5,14]. Nevertheless, it has been shown that subgroups
of patients with stage II colon cancer can benefit from
adjuvant chemotherapy [24]. In fact, high-risk stage II
colorectal cancer patients have a worse prognosis than
single node positive stage III colorectal cancer patients
[28]. Better prediction of relapse as an indication for
the need of adjuvant chemotherapy is thus required for
stage II colorectal cancer [5]. Histopathological and
clinical variables are most frequently used for identify-
ing high-risk stage II colon cancers. Peritoneal involve-
ment, extramural vascular invasion, tumor perforation,
male gender, bowel obstruction, number of nodes har-
vested and presence of lymph node micro metastasis
have all been identified as negative prognostic factors
in stage II colon cancer [16,22,30]. Notwithstanding
this extensive body of work, these histopathological
factors have not yet provided an established basis for
accurately identifying patients at high-risk for relapse
in a clinical setting. Molecular markers can help to se-
lect stage II colon cancer patients with worse progno-
sis. Gene expression profiles have been able to iden-
tify stage II colon cancer patients at high-risk for re-
lapse [4,15]. However, RNA is an instable molecule
and its expression subject to environmental and circa-
dian rhythms. In contrast, DNA is more stable and can
be obtained for copy number analysis from formalin
fixed paraffin embedded (FFPE) material which is fre-
quently the only material available in routine clinical
practice. DNA copy number aberrations are a hallmark
of cancer. These chromosomal aberrations are less fre-
quent in micro satellite instable (MSI) tumors com-
pared to micro satellite stable (MSS) tumors. The latter
group is also referred to Chromosomal Instable (CIN)
and accounts for 85% of all colorectal tumors. MSS
CRCs have a worse outcome than MSI CRCs [41].
In CRC, chromosomal aberrations, important for tu-
mor progression and prognosis, have been studied [12,
18–20,23,29,32], but to which extent specific chromo-
somal changes have prognostic value specifically in
stage II colon cancer patients has only been analyzed
in limited detail. Therefore, the present study analyzed
genome wide DNA copy number changes using high
resolution oligonucleotide based array CGH for iden-
tifying chromosomal aberrations that may be used as
prognostic markers for patients with stage II colon can-
cer.
2. Materials and methods
2.1. Patient and sample selection
Forty patients operated between 1990 and 2000 for
stage II colon cancer (pT3 or pT4, pN0, pM0, R0 TNM
classification, fifth edition [34]) were selected for this
study, 16 with and 24 without relapse. Seventeen pa-
tients underwent resection of their primary tumor at the
John Goligher Colorectal Unit, Leeds General Infir-
mary (UK) and 23 patients at the Zaans Medical Centre
(The Netherlands). Medical records of all patients were
reviewed retrospectively to obtain clinical data, patient
characteristics and follow-up data. None of the patients
received postoperative chemotherapy or radiotherapy.
Tumor relapse was defined as the occurrence of distant
metastasis, confirmed by ultrasound, CT scan and/or
histology within 36 months. Haematoxylin and eosin
(H&E) stained sections were reviewed by a pathologist
for TNM tumor stage [34], differentiation grade, num-
ber of nodes, assessed tumor perforation, extramural
vascular invasion (EMVI) and peritoneal involvement.
All samples were used in compliance with the respec-
tive institutional ethical regulations for surplus ma-
terial and use of material from Leeds General Infir-
mary (UK) was approved by the Leeds (West) research
ethics committee, unique identifier CA02/014.
2.2. DNA isolation from formalin-fixed and
paraffin-embedded (FFPE) tissue blocks
DNA was isolated from FFPE colon cancer tissue of
40 samples. Corresponding normal mucosa DNA was
isolated from 37 of the samples as a reference and was
obtained from the resection margins or at least 1 cm
distance from the tumor. For 3 cases no normal mucosa
was available and a pool of reference DNA isolated
from blood obtained from eighteen healthy males was
used. For each tumor an area containing at least 70%
of tumor cells was marked on the slides. Of the FFPE
blocks 4–6 10 µm sections were cut, deparaffinized and
macro dissected. Isolation of DNA was performed as
previously described [42], including incubation with
sodium thiocyanate (1 M, CNNaS), proteinase K treat-
ment and purification using a column based method
(QIAamp microkit; Qiagen, Hilden, Germany).
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2.3. Microsatellite stability
All samples were analyzed for Microsatellite insta-
bility (MSI) using MSI Analysis System, version 1.1
according to manufacturer’s instructions (Promega,
Madison, WI, USA). This PCR based assay is us-
ing 5 mononucleotide markers to determined MSI
status. PCR product were separated by capillary elec-
trophoresis using ABI 3130 DNA sequencer and out-
put data were analyzed using the accompanying pack-
age GeneScan 3100 (Applied Biosystems, Foster City,
CA, USA). Tumors were classified as micro satellite
instable (MSI) when instability of two or more markers
was seen. When a single or no instable markers were
seen, tumors were considered as micro satellite stable
(MSS).
2.4. Chromosomal copy number analysis by array
comparative genomic hybridization (array CGH)
Labeling and hybridization was done as previously
described [6]. Briefly, 500 ng of genomic DNA of tu-
mor and reference was labeled with either Cyanine
3-UTP (Cy3) or Cyanine 5-UTP (Cy5) nucleotide mix-
ture, respectively, according to manufacturer’s instruc-
tions (CGH labeling Kit for Oligo Arrays, Enzo Life
Sciences, Farmingdale, NY, USA) and purified using
the QIAquick PCR Purification Kit (Qiagen, West-
burg, Leusden, The Netherlands). Labeled tumor and
(matched) reference DNAs were mixed prior to hy-
bridization onto Agilent 4 × 44 K oligonucleotide
arrays (Agilent Technologies, Palo Alto, CA, USA).
Each slide consists of 4 arrays, each containing 45,220
in situ synthesized 60-mer oligonucleotides represent-
ing 42,494 unique biological features distributed over
the genome. Immediately after hybridization the slides
were scanned using microarray scanner G2505B (Ag-
ilent technologies, Palo Alto, CA, USA) and image
analysis was performed using feature extraction soft-
ware (version 9.1, Agilent Technologies, Palo Alto,
CA, USA). The Agilent CGH-v4_91 protocol was
applied using default settings. Oligonucleotides were
mapped according to the human genome build NCBI
36 (May 2006). Of both Cy3 and Cy5 channels, local
background was subtracted from the median intensi-
ties. The log2 tumor to normal intensity ratio was cal-
culated for each spot and normalized against the me-
dian of the ratios of all autosomes.
2.5. Statistical analysis of genomic profiles
Analysis of array CGH data was done in the statisti-
cal computing language R, version 2.6.1 (http://www.
r-project.org). Chromosomal copy number losses and
gains were identified using the package CGHcall [37]
with cellularity set to 0.7 and median normalization. To
reduce the dimension of the array CGH data set with-
out loss of information, regions were defined as previ-
ously described [39].
To calculate significance of DNA copy number dif-
ferences between patients who did and did not relapse,
a Wilcoxon–Mann–Whitney two sample test was used,
implemented in the software package CGHmultiarray,
that provides multiple comparison correction [38]. Dif-
ferences were analyzed for all patients and for MSS
colon cancer patients separately. p-values of <0.05 and
false discovery rates, i.e. the expected proportion of
false positives among the DNA copy numbers claimed
to be correlated with outcome, of <0.15 were consid-
ered to be statistical significant [13].
Statistical analysis of associations with histopatho-
logical and clinical variables was performed using
SPSS software (SPPS for Windows, version 15.0,
SPSS Inc., Chicago, IL, USA). Mann–Whitney U -test
and chi-square test were used for analyzing differ-
ences in continuous or categorical variables, respec-
tively. For correlations with overall survival (OS) and
disease free survival (DFS) univariate survival analy-
sis with log rank statistics was used and Kaplan–Meier
curves were constructed. To determine independent
effects of clinical variables and DNA copy number
changes, multivariate Cox proportional hazard analysis
was performed. OS and DFS were defined as time from
surgery to date of death due to all causes or to date
of first evidence of distant metastasis. p-values <0.05
were considered as statistical significant.
3. Results
3.1. Patient and tumor characteristics
Patient and tumor characteristics of 40 stage II colon
cancer patients are listed in Table 1. Twenty-eight tu-
mors were MSS and 12 MSI. Relapse of tumor oc-
curred in 14 MSS patients and 2 MSI patients (p =
0.05). No significant differences in age, gender, num-
ber of nodes assessed, differentiation grade, T-stage
and other histopathological variables between patients
who relapsed and who did not were seen (Table 1).
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Table 1
Patients and tumor characteristics of stage II colon cancers (N = 40)
No relapse (n = 24) relapse (n = 16)
Mean age (years) (range) 72 (49–91) 73 (54–90) ns$
Mean number of nodes assessed (range) 8.5 (3–17) 7.7 (1–22) ns$
Gender
Female 12 10 ns§
Male 12 6
Location
Right-sided* 18 10 ns§
Left-sided# 6 6
T-stage
T3 23 15 ns§
T4 1 1
Differentiation
Poor 2 3 ns§
Moderate 22 13
Tumor perforation
Yes 0 0 ns§
No 24 16
Peritoneal involvement
Yes 1 1 ns§
No 23 15
EMVI
Yes 2 2 ns§
No 9 4
Unknown 13 10
MSI
Yes 10 2 0.05§
No 14 14
Notes: *Right (caecum, ascending colon, transverse colon, hepatic flexure); #left (splenic flexure, descending colon, sigmoid colon); EMVI –
Extramural vascular invasion; Ns – not significant; $Mann–Whitney U -test; §chi-square.
Mean follow-up time for all patients was 73 months
(range 2–155). A trend was seen for DFS of MSI pa-
tients being better compared to MSS patients, although
this was not significant (5-year DFS 80% vs. 50%,
p = 0.06) (Fig. 1). Survival time for MSS patients with
(n = 14) or without (n = 14) relapse was 23 months
(range 2–59) versus 104 months (range 5–155), respec-
tively.
3.2. DNA copy numbers aberrations in MSS and MSI
stage II colon cancer patients
CGH profiles of 40 stage II colon cancers patients
showed copy number aberrations consistent with those
reported in literature [7,8,12,35,36]. The mean frac-
tion of the genome altered was 15.3% (range 0–44%),
and was significantly higher for MSS tumors (19.4%,
range 0–44%) compared to MSI tumors (5.9%, range
0–18%) (p < 0.001). The amount of losses versus
gains was balanced in the MSS tumors, but MSI tu-
mors showed more gains than losses; gains 4.8% (0–
16.2%) versus losses 1.1% (0–3.1%). Gains in MSI
tumors predominately occurred at 8q24.3 (4 out of
12) and 9p21.3 (4 out of 12) and losses at 6p22.1
(4 out of 12), 16p13.2 (5 out of 12) and 17p13.1 (3
out of 12). For MSS tumors the highest frequency
of aberrations (in more than 12 out of 28 patients)
were gains of chromosome 7p22–p11, 7q11, 7q22,
whole chromosome 13 and 20 and losses of chromo-
some 8p23.1–p12, 15q13.3–q26.1, 17p13.2–p11.2 and
18p11.3–q22.3. DNA copy number changes of MSI
and MSS tumors are summarized in Fig. 2A and B.
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Fig. 1. Kaplan–Meier analysis of disease-free survival for 40 stage II colon cancer patients stratified by MSI/MSS status. MSI colon tumors
showed a trend towards better disease-free survival compared to MSS patients (p = 0.06).
3.3. Differences in DNA copy numbers aberrations
between stage II colon cancer patients with and
without relapse
Overall, significant differences were observed be-
tween patients without or with relapse, with 11.2%
vs. 21.4% of the genome altered (p = 0.005). This
was primarily reflected in the amount of losses which
was 10.9% of the genome for the patients which re-
lapsed versus 3.9% for the patients which remained
disease free (p = 0.002). The chromosomal region(s)
which significantly differed between patients with or
without relapse were losses on chromosome 4p16.1–
p12 (30 Mb), 4q12–q35.2 9 (127 Mb), 5p14 (9 Mb),
5q11.2–q14.2 (21 Mb), 5q32–q34 (0.86 Mb), 15q11.2–
q26.1 (21 Mb), 17q21.1 (0.48 Mb), 18q12.1–q12.3
(15 Mb) and 18q21.1–q22.13 (6 Mb). No significant
difference was observed in the amount of gains, 7.3%
of the genome altered for patients who did not relapse
versus 10.5% for patients that did (p = 0.11).
Also among the 28 MSS patients, more aberrations
were observed in patients who relapsed (p = 0.03), be-
ing mainly losses. Loss of chromosome 4q22.1–4q35.2
(90.5 Mb) was the only significant aberration, being
more frequently deleted in patients with relapse of
tumor. Loss of 4q22.1–4q35.2 was seen in 43–50%
(p = 0.01 to p = 0.004) of patients who relapsed, de-
pending on which boundaries for the lost region were
used. An overview of DNA copy number changes in
MSS patient who either relapsed or not, is presented in
Fig. 3. The number of MSI patients was too small to
further stratify and analyze differences between either
or not relapse occurred.
Both OS and DFS were significantly worse for pa-
tients with loss of chromosome 4q22.1–4q35.2 or part
of that region. Considering any loss on chromosome
4q22.1–4q35.2 predicted worse OS and DFS survival
(5-year OS 70% vs. 5%, p < 0.001; 5-year DFS 75%
vs. 5%, p = 0.004) (Fig. 4). Cox proportional haz-
ard model demonstrated that any loss on chromosome
4q22.1–4q35.2 was an independent prognostic factor
for worse DFS (HR = 15.4, p < 0.001). Age >72.5
year (HR = 6.7, p = 0.04) and any loss on chromo-
some 4q22.1–4q35.2 (HR = 16.9, p < 0.001) were
independent prognostic factors for OS.
4. Discussion
A substantial part of stage II colon cancer patients
currently develop distant metastasis after resection of
their primary tumor and subsequently die of their dis-
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(A)
(B)
Fig. 2. Percentage of chromosomal gains and losses measured by array CGH in (A) 28 MSS and (B) 12 MSI stage II colon cancers patients.
X-axis displays 44,000 oligo-nucleotides in genomic order (chromosomes 1–22). Y -axis displays percentage of tumor with gains (>0) or losses
(<0). Boundaries of chromosomes are indicated by black vertical lines and locations of centromeres are indicated by dotted lines.
ease. Nevertheless, the American Society of Clinical
Oncology (ASCO) [5] and the National Comprehen-
sive Cancer Network (NCCN) [44] independently rec-
ommended against routine administration of adjuvant
therapy in stage II disease, due to a lack of evidence for
the benefit of survival [5,14,17,24,45]. Notwithstand-
ing, it has been suggested that subgroups of stage II
patients will benefit from adjuvant therapy. At present
no objective parameters for selecting these patients
are established [10,28]. Hence, objective and robust
prognostic markers are desirable to select and stratify
stage II colon cancer patients at high-risk for relapse.
The present study found in stage II colon cancer pa-
tients deletion of chromosome 4q to be associated with
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(A)
(B)
Fig. 3. Percentage of chromosomal gains and losses measured by array CGH in 28 MSS stage II colon cancer patients without (A) and with (B)
relapse of disease. X-axis displays 44,000 oligo-nucleotides in genomic order (chromosomes 1–22). Y -axis displays percentage of tumor with
gains (>0) or losses (<0). Boundaries of chromosomes are indicated by black vertical lines and the location of centromeres are indicated by
dotted lines.
relapse of disease. This conclusion is consistent with
literature [1–3,11,12,19] and suggests that it could be
worthwhile further exploring whether patients with
loss of chromosome 4q should be considered for adju-
vant therapy.
Moreover, in the present study significantly more
losses on chromosome 4, 5, 15q, 17q and 18q were
seen in tumors of patients who had cancer relapse.
This observation is validated by the results published
by Sheffer et al. who linked worse prognosis to a si-
multaneous deletion of 4p,15q and 18q in colorectal
cancer [32]. Forty percent (12 of 40) of tumors were
MSI and had 5.9% of their genome altered, which were
primarily gains (4.8%). This is in accordance with re-
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Fig. 4. Kaplan–Meyer disease-free survival plot of 28 MSS stage II colon cancer patients stratified for any loss of chromosome 4q22.1–q35.2.
Stage II colon tumors with any loss on chromosome 4q22.1–q35.2 showed worse disease-free survival than without losses on 4q22.1–q35.2
(p = 0.004).
sults reported by Trautman et al. who reported 2.3%
gain versus 0% loss in 23 MSI and 17.2% gain versus
19.9% loss in 23 MSS sporadic colon cancers analyzed
by BAC array CGH [35].
When MSS patients were analyzed, only losses in
the region of 4q22.1–35.2 occurred significantly more
frequent in patients who relapsed compared to those
who did not. Losses of 4p, 5p, 5q, 15q, 17q and 18q
were associated but not significantly related to relapse
when only MSS patients were analyzed. A likely ex-
planation for this could be a limited sample size and
hence lack of power to detect associations with, e.g.,
18q loss at a statistically significant level. Loss of
18q as prognostic marker in stage II CRC have been
reported previously based on loss of heterozygosity
analysis [21,25]. As no aberrations on chromosome 4
were seen in MSI tumors, loss of 4q appears partic-
ularly relevant for predicting relapse in patients with
stage II MSS colon tumors.
Numerous studies have analyzed the relation of
DNA copy number changes and clinical outcome in
colorectal cancer patients. In only a small number of
studies the prognostic value of chromosomal aberra-
tions limited to patients with early stage colon can-
cer have been analyzed. In 70 stage I and II MSI and
MSS colorectal cancer patients, loss of chromosome
4p was an independent prognostic factor, and loss of
chromosomes 4 and 14q were associated with a worse
prognosis [2]. This study used BAC array CGH and
reported minimally deleted regions at 4q24–28 and
4q32–35, which is consistent with the findings in the
present study [2]. Additional detailed analysis of this
group of patients using low resolution loss of heterozy-
gosity (LOH) analysis showed that in particular loss
of 4p16, 4q31.1 and 4q33.1 was related to prognosis,
further validating our findings [1]. When chromoso-
mal aberrations were studied with CGH in stages I–
IV colorectal tumors, loss of chromosome 4q resulted
in shorter survival times [11], loss of 4q32–34 was
associated with metastasis [3] and loss of 4q35 and
4q31.3 correlated with shorter disease-specific survival
[19]. A meta-analysis of 31 CGH studies encompass-
ing copy number profiles of 373 colorectal tumors and
102 liver metastasis, showed loss of chromosome 4 to
be related to progression from primary tumor to distant
metastasis [12]. Loss of chromosome 4q in relation to
survival does not seem to be CRC specific, but has also
been reported for other epithelial tumors; i.e., bladder
[31], head and neck [9], prostate [26] and breast can-
cer [33]. Deletion of 4q has also been associated with
micro metastasis in lung cancer [46].
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The critical region 4q22.1–35.1 encompasses
90.5 Mb of chromosomal region with 265 coding
genes. The size of the region thus makes it difficult to
pin-point the candidate tumor suppressor genes or non-
coding RNA. Integration of array CGH and gene ex-
pression array or extensive mutation analysis by next
generation sequencing could possibly further narrow
down the number of candidate driver genes.
In summary, loss of chromosome 4q22.1–35.1 may
predict relapse of disease in stage II colon cancer pa-
tients. Chromosome 4q may thus have important prog-
nostic value for patient tailored therapy.
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